Document is current
Any future updates will be listed below
-
Authors
Harper, Rebecca L.
Zhou, Xin
Marciano, David P.
Cao, Aiqin
Wang, Lingli
Chen, Guibin
Adil, Mir S.
Zhou, Wenyu
Maguire, Peter
Deivanayagam, Shanthi
Yu, Quan
Viswanathan, Vignesh
Yang, Dan
Martin, Marcy
Isobe, Sarasa
Otsuki, Shoichiro
Burgess, Jordan
Inglis, Audrey
Kelley, Devon
del Rosario, Patricia A.
Hsi, Andrew
Haddad, Francois
Zamanian, Roham T.
Boehm, Manfred
Snyder, Michael P.
Rabinovitch, Marlene
-
Funding
Funding for this research was provided by:
National Institutes of Health,United States (P30 AG059307, P01 HL108797, S10 OD025212, P30 DK116074, P01 HL108797)
American Heart Association (20POST35080009)
Mie Univeristy Graduate School of Medicine (NA)
Dunlevie Chair in Pediatric Cardiology at Stanford University (NA)
- License Information
-
More Information
Article History
Received: 9 August 2024
Accepted: 7 March 2025
First Online: 15 April 2025
Declarations
:
: All human samples used were coded and all patients and controls signed an informed consent under protocols approved by the Institutional Review Board on Human Subjects in Medical Research at Stanford University. The Animal Care Committee at Stanford University approved all the experimental protocols used in this study in accordance with the guidelines of the American Physiological Society.
: Not applicable.
: M.P.S. is a co-founder and scientific advisor for Crosshair Therapeutics, Exposomics, Filtricine, Fodsel, Iollo, InVu Health, January AI, Marble Therapeutics, Mirvie, Next Thought AI, Orange Street Ventures, Personalis, Protos Biologics, Qbio, RTHM, SensOmics. M.P.S. serves as a scientific advisor for Abbratech, Applied Cognition, Enovone, Jupiter Therapeutics, M3 Helium, Mitrix, Neuvivo, Onza, Sigil Biosciences, TranscribeGlass, WndrHLTH, Yuvan Research. M.P.S. is a co-founder of NiMo Therapeutics. M.P.S. is an investor and scientific advisor of R42 and Swaza. M.P.S. is an investor in Repair Biotechnologies. The other authors declare no competing interest.
